Published in Lupus on October 01, 2009
Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol (2012) 1.27
Ethnic differences in cardiovascular risk in rheumatic disease: focus on Asians. Nat Rev Rheumatol (2011) 0.80
Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review. Autoimmune Dis (2013) 0.80
Cardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry. Medicine (Baltimore) (2015) 0.80
Frequency of established cardiovascular disease and its risk factors in Chinese patients with systemic lupus erythematosus. Clin Rheumatol (2011) 0.79
Nephritis and the risk of acute myocardial infarction in patients with systemic lupus erythematosus. Clin Exp Rheumatol (2010) 0.77
Serum Resistin Level and Progression of Atherosclerosis during Glucocorticoid Therapy for Systemic Autoimmune Diseases. Metabolites (2016) 0.75
Cardiovascular disease in immune-mediated inflammatory diseases: A cross-sectional analysis of 6 cohorts. Medicine (Baltimore) (2017) 0.75
The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1982) 67.54
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1997) 43.47
Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol (1997) 6.10
Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum (2001) 5.36
Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) (2003) 4.00
Risk factors for the progression of coronary artery calcification in asymptomatic subjects: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation (2007) 3.90
Systemic effects of smoking. Chest (2007) 3.63
Mortality in systemic lupus erythematosus. Arthritis Rheum (2006) 3.61
Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA (2006) 3.26
Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum (2004) 2.88
Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. Circulation (1997) 2.54
Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum (1999) 2.36
Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. J Mol Med (Berl) (2005) 2.29
The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol (2000) 2.26
Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus (2002) 2.03
Genetic variation is associated with C-reactive protein levels in the Third National Health and Nutrition Examination Survey. Circulation (2006) 2.00
Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet (2003) 1.98
Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost (1996) 1.88
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum (2004) 1.75
Relation between markers of systemic vascular inflammation and smoking in women. Am J Cardiol (2002) 1.73
Risk for incident arterial or venous vascular events varies over the course of systemic lupus erythematosus. J Rheumatol (2006) 1.65
Polymorphism of the C-reactive protein (CRP) gene is related to serum CRP Level and arterial pulse wave velocity in healthy elderly Japanese. Hypertens Res (2006) 1.52
Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol (1995) 1.52
Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis (2002) 1.42
Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum (2005) 1.41
Time to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohort. PLoS Med (2006) 1.34
Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol (2004) 1.33
Clinical prognostic factors in lupus nephritis. The importance of hypertension and smoking. Arch Intern Med (1992) 1.29
Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford) (2004) 1.24
Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine (Baltimore) (1992) 1.15
Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet (1996) 1.14
Established risk factors account for most of the racial differences in cardiovascular disease mortality. PLoS One (2007) 1.12
Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. Rheumatology (Oxford) (2007) 1.09
Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. Arthritis Rheum (2006) 1.09
Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol (2000) 1.09
Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J Rheumatol (1998) 1.09
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum (2005) 1.05
Epileptic seizures in cerebral arterial occlusive disease. Stroke (1982) 1.05
Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center. Semin Arthritis Rheum (2004) 1.00
The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. Thromb Res (2004) 1.00
Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol (2006) 0.99
Systemic lupus erythematosus in a multiethnic US Cohort (LUMINA). XXX: association between C-reactive protein (CRP) gene polymorphisms and vascular events. Rheumatology (Oxford) (2005) 0.92
Mortality associated with incident mental health disorders after stroke. Aust N Z J Psychiatry (2007) 0.92
Cigarette smoking and disease activity in systemic lupus erythematosus. J Rheumatol (2003) 0.91
Lupus and thrombosis. J Rheumatol (2006) 0.90
Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus (2007) 0.90
Homocysteine, methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus: a retrospective cohort study. J Rheumatol (1998) 0.88
Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J Thromb Haemost (2007) 0.87
Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus. Arthritis Rheum (2005) 0.87
Cerebral manifestations in the antiphospholipid (Hughes) syndrome. Rheum Dis Clin North Am (2006) 0.81
Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome. Haematologica (2000) 0.81
Systemic lupus erythematosus in a multiethnic US cohort LUMINA LI: anaemia as a predictor of disease activity and damage accrual. Rheumatology (Oxford) (2007) 0.81
Factor XII autoantibodies as a novel marker for thrombosis and adverse obstetric history in patients with systemic lupus erythematosus. Ann Rheum Dis (2006) 0.79
Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus. J Rheumatol (2005) 0.78
Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus. Lupus (2004) 0.78
[Factors related to the risk of thrombosis in patients with lupus and antiphospholipid antibodies]. Med Clin (Barc) (2006) 0.77
Whole blood viscosity and arterial thrombotic events in patients with systemic lupus erythematosus. Arthritis Rheum (2007) 0.77
The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum (1996) 6.88
Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann Intern Med (1995) 5.18
Increased risk of lymphoma in sicca syndrome. Ann Intern Med (1978) 4.63
Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N Engl J Med (1979) 4.52
Visual processing impairment and risk of motor vehicle crash among older adults. JAMA (1998) 4.49
Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol (2001) 3.87
Mortality in systemic lupus erythematosus. Arthritis Rheum (2006) 3.61
Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med (1994) 3.53
Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees. Proc Natl Acad Sci U S A (1998) 3.35
Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum (1994) 3.15
Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood (1991) 2.92
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med (2001) 2.87
Sociocultural issues in clinical research. Arthritis Rheum (2001) 2.71
Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum (2001) 2.68
Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum (2001) 2.68
The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum (1990) 2.59
Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol (1997) 2.59
Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther (2007) 2.54
Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum (1993) 2.49
The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum (1997) 2.49
A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest (1997) 2.48
Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest (1996) 2.39
Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum (1995) 2.38
Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. J Mol Med (Berl) (2005) 2.29
The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol (2000) 2.26
Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum (2007) 2.18
Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis Rheum (2001) 2.13
Validation of a Systemic Lupus Activity Questionnaire (SLAQ) for population studies. Lupus (2003) 2.11
Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest (1996) 2.09
Cardiac involvement in systemic lupus erythematosus. Lupus (2005) 2.08
Vision impairment, eye disease, and injurious motor vehicle crashes in the elderly. Ophthalmic Epidemiol (1998) 2.07
Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum (2000) 2.06
Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus (2002) 2.03
Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med (1986) 2.01
Reduction of renal function by newer nonsteroidal anti-inflammatory drugs. Am J Med (1978) 1.96
An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum (2005) 1.96
Clinical characteristics affecting survival in patients with rheumatoid arthritis undergoing cervical spine surgery: a controlled study. J Rheumatol (1989) 1.95
Vision impairment and driving. Surv Ophthalmol (1999) 1.95
Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum (1997) 1.92
Radiographic assessment and psychologic variables as predictors of pain and functional impairment in osteoarthritis of the knee or hip. Arthritis Rheum (1988) 1.91
Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol (1998) 1.88
Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum (1985) 1.88
Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug. J Rheumatol (1999) 1.87
Most African-American patients with rheumatoid arthritis do not have the rheumatoid antigenic determinant (epitope) Ann Intern Med (1995) 1.86
Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus (2002) 1.85
Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2010) 1.84
Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol (2001) 1.84
A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum (2001) 1.82
Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci U S A (1996) 1.82
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis (2013) 1.81
Visual and medical risk factors for motor vehicle collision involvement among older drivers. Br J Ophthalmol (2008) 1.79
Interaction of virulent and avirulent Listeria monocytogenes with cultured mouse peritoneal macrophages. Infect Immun (1973) 1.79
Psychiatric diagnoses in patients with fibromyalgia are related to health care-seeking behavior rather than to illness. Arthritis Rheum (1996) 1.77
Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa. J Immunol (1994) 1.76
Blockade of clearance of immune complexes by an anti-Fc gamma receptor monoclonal antibody. J Exp Med (1986) 1.75
Evidence that autoimmunity in man is a Mendelian dominant trait. Am J Hum Genet (1986) 1.74
The histologic spectrum of prepuces from patients with phimosis. Am J Dermatopathol (1988) 1.73
Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun (2011) 1.70
Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function. J Clin Invest (1992) 1.69
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis (2009) 1.69
Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol (1989) 1.67
Factors related to driving difficulty and habits in older drivers. Accid Anal Prev (2001) 1.67
Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Medicine (Baltimore) (1987) 1.67
Genetics of systemic lupus erythematosus. Rheum Dis Clin North Am (1992) 1.66
Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. Arthritis Rheum (2008) 1.65
A new promising treatment in systemic sclerosis: 5-fluorouracil. Ann Rheum Dis (1987) 1.62
Articular involvement in human brucellosis: a retrospective analysis of 304 cases. Semin Arthritis Rheum (1982) 1.62
Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum (1992) 1.62